Literature DB >> 3925539

Quantitative absorption of interleukin-2 by peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis.

C Knobloch, M Schlesier, R Dräger, M Gärtner, H H Peter.   

Abstract

Peripheral blood (PBL) and synovial fluid lymphocytes (SFL) from 18 patients with definite rheumatoid arthritis (RA) and from one patient with Reiter's disease (RD) were examined for their capacity to absorb quantitatively interleukin-2 (IL-2) from a standardized, lectin-free IL-2 source. For comparison normal ConA blasts and PBL from various inflammatory and noninflammatory diseases as well as from healthy control persons were studied. IL-2 activity was quantitated by measuring 3H-thymidine-2-deoxyriboside uptake in the IL-2 dependent murine T cell line CTL6. ConA blasts exhibited a high IL-2 absorption capacity and served as a positive control for calibrating the absorption assay. In a population of normal PBL at least 5-10% of ConA blasts were required to detect IL-2 absorption. Significant absorption was assumed if more than 50% of IL-2 activity was removed from 200 microliters of a lectin-free IL-2 standard following incubation with 5 X 10(6) lymphoid cells for 2 h at 4 degrees C; this criterion was fulfilled with 8 out of 20 SFL and 4 out of 14 PBL preparations from RA patients. As a rule SFL absorbed more IL-2 than PBL. Control PBL did not absorb significant quantities of IL-2. PBL from the RD patient apparently produced an IL-2 inhibitor during incubation with the IL-2 standard. IL-2 absorption by ConA blasts and SFL was fully inhibited by preincubation of the absorbing cells with monoclonal anti-TAC antibody, a reagent known to react with the human IL-2 receptor. The results are discussed in view of current concepts of antigen/mitogen induced T cell activation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925539     DOI: 10.1007/bf00541333

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

3.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

Authors:  T Uchiyama; D L Nelson; T A Fleisher; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

4.  Ligand-activated T cell growth factor-induced proliferation: absorption of T cell growth factor by activated T cells.

Authors:  G D Bonnard; K Yasaka; D Jacobson
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

5.  Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity.

Authors:  K Welte; C Y Wang; R Mertelsmann; S Venuta; S P Feldman; M A Moore
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

6.  Immunologic effects of interleukin 2 in primary immunodeficiency diseases.

Authors:  N Flomenberg; K Welte; R Mertelsmann; N Kernan; N Ciobanu; S Venuta; S Feldman; G Kruger; D Kirkpatrick; B Dupont; R O'Reilly
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

Authors:  M Linker-Israeli; A C Bakke; R C Kitridou; S Gendler; S Gillis; D A Horwitz
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.

Authors:  J M Depper; W J Leonard; R J Robb; T A Waldmann; W C Greene
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

9.  Sequential expression of T cell activation (Tac) antigen and Ia determinants on circulating human T cells after immunization with tetanus toxoid.

Authors:  A Yachie; T Miyawaki; N Uwadana; S Ohzeki; N Taniguchi
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

10.  T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity.

Authors:  H Wagner; M Röllinghoff
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  5 in total

1.  Occurrence of interleukin-1 in human synovial fluid: detection by RIA, bioassay and presence of bioassay-inhibiting factors.

Authors:  J B Smith; M H Bocchieri; L Sherbin-Allen; M Borofsky; J L Abruzzo
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

Review 2.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  P E Lipsky; L S Davis; J J Cush; N Oppenheimer-Marks
Journal:  Springer Semin Immunopathol       Date:  1989

Review 3.  T cell regulation and T cell clones in relation to synovial inflammation.

Authors:  G R Burmester; B Jahn; N Hain; G Strobel; J R Kalden
Journal:  Springer Semin Immunopathol       Date:  1989

4.  Interleukin 2 inhibitor in synovial fluid.

Authors:  P Emery; K C Gentry; A Kelso; I R Mackay
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

5.  Analysis of T-cell cultures and clones from a patient with classic rheumatoid arthritis--evidence for the existence of autoreactive T-cell clones in blood and synovial fluid.

Authors:  M Schlesier; C Ramb-Lindhauer; M Gärtner; H H Peter
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.